Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...

Several drugs that inhibit epigenetic writers and ... These include DNA methyltransferase and histone deacetylase (HDAC) inhibitors. Further candidates, including inhibitors of acetyl-lysine ...

Italfarmaco's marketing application for HDAC inhibitor givinostat as a treatment ... The Milan-based drugmaker filed for approval of the drug in the US earlier this year, with a priority review ...

Additionally, the platform supports combination therapies using hedgehog pathway inhibitors alongside HDAC inhibitors to amplify ... as highly potent, specific drug candidates aimed at rare ...

Detailed price information for Windtree Therapeutics Inc (WINT-Q) from The Globe and Mail including charting and trades.

PhD Defense of W.P.J. Cox (UMC Utrecht/Kinderen) ...